Immunic targeting mental and physical challenges facing MS patients - ICYMI

Core Insights - Immunic Inc is focusing on addressing both physical and mental health challenges faced by multiple sclerosis (MS) patients, recognizing the strong link between MS and mental health issues such as depression and anxiety [1][2][3] Research Focus - The company emphasizes the importance of treating MS as more than just a neurological disease, highlighting that approximately 30% of MS patients experience depression and around 20% experience anxiety [2][3] - Immunic's research aims to slow disease progression, particularly focusing on progression independent of relapse activity (PIRA), which accounts for at least 50% of disability accumulation in relapsing-remitting MS [3][4] Treatment Development - Immunic is dedicated to addressing unmet needs in all forms of MS, especially for patients with primary progressive MS (PPMS), where over 50% experience depressive symptoms and treatment options are limited [4] - The company has reported positive data from its Phase 2 clinical trials, including the EMPhASIS trial and CALLIPER trial, which focus on the drug vidofludimus calcium [3][4] Vision for Future Treatment - The vision for future MS treatments includes a holistic approach that integrates mental health support into every stage of care, aiming for effective and tolerable treatments that improve patients' overall quality of life [5][6]